AU2021469435A1 - Device and method for dilation of a tubular anatomical structure - Google Patents
Device and method for dilation of a tubular anatomical structure Download PDFInfo
- Publication number
- AU2021469435A1 AU2021469435A1 AU2021469435A AU2021469435A AU2021469435A1 AU 2021469435 A1 AU2021469435 A1 AU 2021469435A1 AU 2021469435 A AU2021469435 A AU 2021469435A AU 2021469435 A AU2021469435 A AU 2021469435A AU 2021469435 A1 AU2021469435 A1 AU 2021469435A1
- Authority
- AU
- Australia
- Prior art keywords
- optical fiber
- dilation
- artery
- tip
- conical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000010339 dilation Effects 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 79
- 210000003484 anatomy Anatomy 0.000 title claims abstract description 36
- 239000013307 optical fiber Substances 0.000 claims abstract description 125
- 210000001367 artery Anatomy 0.000 claims abstract description 67
- 238000013151 thrombectomy Methods 0.000 claims abstract description 44
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000000916 dilatatory effect Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 72
- 229910003460 diamond Inorganic materials 0.000 claims description 41
- 239000010432 diamond Substances 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000005350 fused silica glass Substances 0.000 claims description 22
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 20
- 230000003287 optical effect Effects 0.000 claims description 9
- 150000002826 nitrites Chemical class 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 4
- 210000003123 bronchiole Anatomy 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- 210000005239 tubule Anatomy 0.000 claims description 3
- 210000000626 ureter Anatomy 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 abstract description 54
- 238000000605 extraction Methods 0.000 abstract description 16
- 230000002085 persistent effect Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 238000004090 dissolution Methods 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 230000001678 irradiating effect Effects 0.000 abstract description 2
- 230000006378 damage Effects 0.000 description 27
- 239000000835 fiber Substances 0.000 description 27
- 239000000377 silicon dioxide Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 208000031481 Pathologic Constriction Diseases 0.000 description 13
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 229920003023 plastic Polymers 0.000 description 12
- 230000024883 vasodilation Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 230000002792 vascular Effects 0.000 description 10
- 229910052688 Gadolinium Inorganic materials 0.000 description 9
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 9
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 9
- 229910001928 zirconium oxide Inorganic materials 0.000 description 9
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 210000001841 basilar artery Anatomy 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000036262 stenosis Effects 0.000 description 7
- 208000037804 stenosis Diseases 0.000 description 7
- 239000012780 transparent material Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 210000001147 pulmonary artery Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 4
- 206010047163 Vasospasm Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- -1 argon ion Chemical class 0.000 description 3
- 208000021328 arterial occlusion Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000021138 brain aneurysm Diseases 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005566 electron beam evaporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000010417 nitric oxide pathway Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920013744 specialty plastic Polymers 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
- G02B6/24—Coupling light guides
- G02B6/26—Optical coupling means
- G02B6/262—Optical details of coupling light into, or out of, or between fibre ends, e.g. special fibre end shapes or associated optical elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00404—Blood vessels other than those in or around the heart
- A61B2018/0041—Removal of thrombosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N2005/0602—Apparatus for use inside the body for treatment of blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0604—Lungs and/or airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/061—Bladder and/or urethra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Laser Surgery Devices (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/056347 WO2023069118A1 (fr) | 2021-10-22 | 2021-10-22 | Dispositif et procédé de dilatation d'une structure anatomique tubulaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021469435A1 true AU2021469435A1 (en) | 2024-05-30 |
Family
ID=86058515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021469435A Pending AU2021469435A1 (en) | 2021-10-22 | 2021-10-22 | Device and method for dilation of a tubular anatomical structure |
Country Status (5)
| Country | Link |
|---|---|
| AU (1) | AU2021469435A1 (fr) |
| CA (1) | CA3235810A1 (fr) |
| CO (1) | CO2024006254A2 (fr) |
| IL (1) | IL312331A (fr) |
| WO (1) | WO2023069118A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5303324A (en) * | 1992-10-29 | 1994-04-12 | American Cyanamid Company | Method and apparatus for providing controlled light distribution from a cylindrical fiberoptic diffuser |
| US6539944B1 (en) * | 1999-06-11 | 2003-04-01 | Brant D. Watson | Dethrombosis facilitated by vasodilation |
| CA2475111A1 (fr) * | 2002-02-05 | 2003-08-14 | Pharmacyclics, Inc. | Dispositif de transmission de lumiere faisant intervenir un systeme de diffusion conique et son procede de fabrication |
| BR122020024964B1 (pt) * | 2015-07-28 | 2024-01-16 | Know Bio, Llc | Métodos e dispositivos para reduzir a presença, a concentração ou o crescimento de patógenos dentro ou sobre tecido de mamíferos vivos |
-
2021
- 2021-10-22 AU AU2021469435A patent/AU2021469435A1/en active Pending
- 2021-10-22 IL IL312331A patent/IL312331A/en unknown
- 2021-10-22 WO PCT/US2021/056347 patent/WO2023069118A1/fr active Application Filing
- 2021-10-22 CA CA3235810A patent/CA3235810A1/fr active Pending
-
2024
- 2024-05-16 CO CONC2024/0006254A patent/CO2024006254A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL312331A (en) | 2024-06-01 |
| CA3235810A1 (fr) | 2023-04-27 |
| CO2024006254A2 (es) | 2024-06-27 |
| WO2023069118A1 (fr) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dretler | An evaluation of ureteral laser lithotripsy: 225 consecutive patients | |
| Abela et al. | Laser angioplasty with angioscopic guidance in humans | |
| CA2569428C (fr) | Methodes et dispositifs pour le traitement de la plaque vulnerable | |
| US5593403A (en) | Method for modifying a stent in an implanted site | |
| US5019075A (en) | Method and apparatus for angioplasty | |
| US4799479A (en) | Method and apparatus for angioplasty | |
| US6962584B1 (en) | Electromagnetic photonic catheter for reducing restenosis | |
| JPS6173644A (ja) | 血管再生装置およびその使用方法 | |
| JPH06501859A (ja) | 紫外線照射による再狭窄の抑制 | |
| US6539944B1 (en) | Dethrombosis facilitated by vasodilation | |
| US20230270498A1 (en) | Device and method for dilation of a tubular anatomical structure | |
| WO2003057060A1 (fr) | Methode de traitement des occlusions vasculaires par inhibition de l'agregation plaquettaire | |
| US11963720B2 (en) | Device and method for dilation of a tubular anatomical structure | |
| WO2023069118A1 (fr) | Dispositif et procédé de dilatation d'une structure anatomique tubulaire | |
| WO2023183896A2 (fr) | Dispositif et procédé de dilatation d'une structure anatomique tubulaire | |
| KR20240093569A (ko) | 관형 해부학적 구조체의 확장을 위한 장치 및 방법 | |
| Takekawa et al. | Laser Angioplasty-Fundamental Studies and Initial Clinical Experience | |
| Gal et al. | Silver Halide Fibers For Surgical Applications Of CO [sub] 2 [/sub] Laser | |
| KR102550642B1 (ko) | 홀렙(HoLEP)을 이용한 양성전립선비대증(BPH) 치료의 최적화 | |
| Verdaasdonck et al. | Multifiber excimer laser catheter design strategies for various medical applications | |
| Geschwind et al. | Recanalization of human arteries using Nd-YAG laser carried by optical fibre | |
| ROSIN et al. | A review of technical and clinical aspects of biliary laser lithotripsy | |
| Leeuwen et al. | Multifiber excimer laser catheter design strategies for various medical applications | |
| Michaels et al. | The current status of laser angioplasty | |
| MORIUCHI et al. | A comparison of excimer laser, thermal probe, and mechanical devices for recanalizing occluded human arteries |